03.04.2024 • News

Sika Acquires Concrete Refurbishment Company in the US

Swiss construction chemicals major Sika has acquired Kwik Bond Polymers (KBP), a US-based manufacturer of polymer systems for the refurbishment of concrete infrastructure. Financial details of the transaction were not disclosed.

KBP has production facilities at its headquarters in Benicia, California, and additional production and warehousing near Pittsburgh, Pennsylvania. Its portfolio includes polymer technologies for long-lasting protection of bridge decks and other concrete infrastructure applications.

According to Sika, KBP’s solutions contribute to an overall carbon footprint reduction in the construction industry by increasing the lifespan of construction projects.

Infrastructure in the USA is facing unprecedented challenges due to lack of maintenance and under-investment over many years, Sika commented in a statement. In 2022, a $1.2 trillion infrastructure bill was approved that will support decade-long funding for critical infrastructure upgrades.

Mike Campion, Sika’s regional manager Americas, said: "Kwik Bond is a perfect complement to Sika’s current infrastructure focus and product portfolio. By preserving and extending the service-life of our concrete infrastructure, we deliver outstanding customer value and significant sustainability benefits to the construction industry."

© Victor Maffe/iStockphoto
© Victor Maffe/iStockphoto

Company

Logo:

Sika AG

Zugerstrasse 50
CH-6340 Baar (ZG)
Switzerland

Company contact







Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read